Related Experiment Video
Updated: Aug 26, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Neal M Dixit1, Boback Ziaeian2, Gregg C Fonarow3
1Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: https://twitter.com/NealDixit.
Abstract:
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a recent addition to the pillars of medical therapy for heart failure (HF) with reduced ejection fraction, all of which improve quality of life, morbidity, and mortality. These benefits are evident within the first 30 days of initiation. This review discusses the rationale for SGLT2i initiation in simultaneous or in rapid sequence with other guideline-directed medical therapy (GDMT). We also discuss SGLT2i use and early benefits in HF patients with an ejection fraction greater than 40%.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Inotropic Agents
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Diuretics

